Expansions at sites in Le Mans and Mourenx, France have solidified the CDMO’s position in targeting the hot antibody-drug conjugate and peptide purification markets.
The move comes as demand for peptide and oligonucleotide therapeutics continues to accelerate, particularly in light of projected growth in the obesity drug market.
The CDMO will develop and qualify analytical methods, optimize the formulation, scale up production, and manufacture a cGMP batch of KAD101 to support clinical studies.
